1. CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
   Xue Zhou et al, 2022, Cardiovascular Drugs and Therapy CrossRef
2. Circulating microparticles are associated with clinical severity of persistent ST-segment elevation myocardial infarction complicated with cardiogenic shock
   A. Sionis et al, 2018, International Journal of Cardiology CrossRef
3. Increased circulating leukocyte-derived microparticles in ischemic cerebrovascular disease
   Zhangping He et al, 2017, Thrombosis Research CrossRef
4. Procoagulant effect of extracellular vesicles in patients after transcatheter aortic valve replacement or transcatheter aortic valve replacement with percutaneous coronary intervention
   Hang Chi et al, 2023, Journal of Thrombosis and Thrombolysis CrossRef
5. Interplay of pro-inflammatory cytokines, pro-inflammatory microparticles and oxidative stress and recurrent ventricular arrhythmias in elderly patients after coronary stent implantations
   Xia Li et al, 2021, Cytokine CrossRef
6. Cell-Derived Microparticles and Acute Coronary Syndromes: Is there a Predictive Role for Microparticles?
   Effimia Zacharia et al, 2020, Current Medicinal Chemistry CrossRef
7. Molecular Mechanisms Underpinning Microparticle-Mediated Cellular Injury in Cardiovascular Complications Associated with Diabetes
   Tarek Benameur et al, 2019, Oxidative Medicine and Cellular Longevity CrossRef
8. The Role of Cell-derived Microparticles in Cardiovascular Diseases: Current Concepts
   Panagiota K. Stampouloglou et al, 2022, Current Pharmaceutical Design CrossRef
9. Microparticles and cardiovascular diseases
   Christos Voukalis et al, 2019, Annals of Medicine CrossRef